NeoGenomics Statistics
Total Valuation
NeoGenomics has a market cap or net worth of $806.07 million. The enterprise value is $1.05 billion.
Important Dates
The last earnings date was Tuesday, July 29, 2025, before market open.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NeoGenomics has 129.18 million shares outstanding. The number of shares has increased by 1.05% in one year.
| Current Share Class | 129.18M |
| Shares Outstanding | 129.18M |
| Shares Change (YoY) | +1.05% |
| Shares Change (QoQ) | +0.45% |
| Owned by Insiders (%) | 1.25% |
| Owned by Institutions (%) | 97.08% |
| Float | 127.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 49.25 |
| PS Ratio | 1.15 |
| Forward PS | 1.03 |
| PB Ratio | 0.94 |
| P/TBV Ratio | 28.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 57.38 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.92, with a Debt / Equity ratio of 0.48.
| Current Ratio | 3.92 |
| Quick Ratio | 3.17 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | 108.13 |
| Debt / FCF | n/a |
| Interest Coverage | -13.57 |
Financial Efficiency
Return on equity (ROE) is -11.76% and return on invested capital (ROIC) is -3.54%.
| Return on Equity (ROE) | -11.76% |
| Return on Assets (ROA) | -3.25% |
| Return on Invested Capital (ROIC) | -3.54% |
| Return on Capital Employed (ROCE) | -6.10% |
| Revenue Per Employee | $313,268 |
| Profits Per Employee | -$47,290 |
| Employee Count | 2,200 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 13.49 |
Taxes
| Income Tax | -1.41M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.83% in the last 52 weeks. The beta is 1.54, so NeoGenomics's price volatility has been higher than the market average.
| Beta (5Y) | 1.54 |
| 52-Week Price Change | -60.83% |
| 50-Day Moving Average | 6.74 |
| 200-Day Moving Average | 11.05 |
| Relative Strength Index (RSI) | 51.08 |
| Average Volume (20 Days) | 3,118,752 |
Short Selling Information
| Short Interest | 5.02M |
| Short Previous Month | 4.27M |
| Short % of Shares Out | 3.88% |
| Short % of Float | 3.94% |
| Short Ratio (days to cover) | 2.08 |
Income Statement
In the last 12 months, NeoGenomics had revenue of $689.19 million and -$104.04 million in losses. Loss per share was -$0.82.
| Revenue | 689.19M |
| Gross Profit | 302.24M |
| Operating Income | -78.94M |
| Pretax Income | -83.44M |
| Net Income | -104.04M |
| EBITDA | -7.78M |
| EBIT | -78.94M |
| Loss Per Share | -$0.82 |
Full Income StatementBalance Sheet
The company has $163.69 million in cash and $411.76 million in debt, giving a net cash position of -$248.08 million or -$1.92 per share.
| Cash & Cash Equivalents | 163.69M |
| Total Debt | 411.76M |
| Net Cash | -248.08M |
| Net Cash Per Share | -$1.92 |
| Equity (Book Value) | 854.04M |
| Book Value Per Share | 6.64 |
| Working Capital | 292.43M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $14.05 million and capital expenditures -$33.22 million, giving a free cash flow of -$19.17 million.
| Operating Cash Flow | 14.05M |
| Capital Expenditures | -33.22M |
| Free Cash Flow | -19.17M |
| FCF Per Share | -$0.15 |
Full Cash Flow StatementMargins
Gross margin is 43.85%, with operating and profit margins of -11.45% and -15.10%.
| Gross Margin | 43.85% |
| Operating Margin | -11.45% |
| Pretax Margin | -15.30% |
| Profit Margin | -15.10% |
| EBITDA Margin | -1.13% |
| EBIT Margin | -11.45% |
| FCF Margin | n/a |
Dividends & Yields
NeoGenomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.05% |
| Shareholder Yield | -1.05% |
| Earnings Yield | -12.91% |
| FCF Yield | -2.38% |
Dividend DetailsAnalyst Forecast
The average price target for NeoGenomics is $12.00, which is 92.31% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.00 |
| Price Target Difference | 92.31% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 11.88% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 16, 2003. It was a reverse split with a ratio of 1:100.
| Last Split Date | Apr 16, 2003 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
NeoGenomics has an Altman Z-Score of 2.01 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.01 |
| Piotroski F-Score | 5 |